Vividion Therapeutics
Chemoproteomics platform for discovering covalent small-molecule drugs targeting previously undruggable proteins
- Sector
- Biotech
- Founded
- 2013
- Latest Form D
- $135M, Mar 2021
- Total capital
- $241M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $241M
- 4 Form D · last Mar 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 38 pending · first 2025
- Rank in peer group#59 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$135M
- Private capital raisedForm D · SEC · 3rd filing$82M
- Private capital raisedForm D · SEC · 2nd filing$20.2M
- Private capital raisedForm D · SEC · 1st filing$3.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#59 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Benjamin K. CravattDirectorNamed in SEC Form D filings
- Diego K. MirallesExecutive Officer, DirectorNamed in SEC Form D filings
- Fred K. AslanExecutive OfficerNamed in SEC Form D filings
- Jakob LovenDirectorNamed in SEC Form D filings
- Jeffrey HatfieldExecutive Officer, DirectorNamed in SEC Form D filings
- John ClarkeDirectorNamed in SEC Form D filings
Show all 15 people
- John K. ParkExecutive OfficerNamed in SEC Form D filings
- Kristina BurowDirectorNamed in SEC Form D filings
- Patricia L. AllenExecutive OfficerNamed in SEC Form D filings
- Patricia L. AllenExecutive OfficerNamed in SEC Form D filings
- Richard K. HeymanDirectorNamed in SEC Form D filings
- Thomas E. DanielDirectorNamed in SEC Form D filings
- Thomas E. DanielDirectorNamed in SEC Form D filings
- Thomas K. WoiwodeDirectorNamed in SEC Form D filings
- Tom K. DanielDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 40- GrantedInhibitors And Uses ThereofUSPTOUS 12,740,991
- PendingInhibitors And Uses ThereofUSPTOApplication 19384506
- PendingPharmaceutical Compositions Comprising Wrn Helicase InhibitorsUSPTOApplication 18872049
Show all 40 patent records
- Inhibitors And Uses ThereofSep 22, 2026 · US 12,740,991Granted
- Inhibitors And Uses ThereofJul 23, 2026 · Application 19384506Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsOct 30, 2025 · Application 18872049Pending
- Crystalline Form Of (R)-1-(3-(3-(4-AMINOPYRIMIDIN-2-YL)-5-CHLOROPHENYL)MORPHOLINO)PROP-2-EN-1-ONEJul 17, 2025 · Application 19096630Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsJun 12, 2025 · Application 18975372Pending
- Compounds And Methods For Modulating STAT3Feb 20, 2025 · Application 18593361Pending
- Compounds And Methods For Modulating RAS-PI3KJan 23, 2025 · Application 18589169Pending
- KEAP1 Inhibitors And Uses ThereofJan 9, 2025 · Application 18742689Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsJan 7, 2025 · US 12,187,685Granted
- Compounds Selective For JAK1 And Methods Of UseAug 15, 2024 · Application 18563329Pending
- Inhibitors And Uses ThereofJul 11, 2024 · Application 18477240Pending
- Compounds And Methods For Modulating Immune-related ProteinsApr 18, 2024 · Application 17768641Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsFeb 29, 2024 · Application 18218149Pending
- Substituted Isoindolinones As Modulators Of Cereblon-mediated Neo-substrate RecruitmentFeb 9, 2023 · Application 17299761Pending
- Compounds And Methods Of Modulating Protein DegradationJul 30, 2020 · Application 16650765Pending
- JAK1 Inhibitors And Uses ThereofApplication 63579527Pending
- Inhibitors And Uses ThereofApplication 63519541Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsApplication PCTUS2023026888Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsApplication PCTUS2023026886Pending
- KEAP1 Inhibitors And Uses ThereofApplication 63508174Pending
- Compounds And Methods For Modulating STAT3Application 63488117Pending
- Compounds And Methods For Modulating RAS-PI3KApplication 63487475Pending
- Compounds And Methods For Modulating RAS-PI3KApplication 63487431Pending
- Inhibitors And Uses ThereofApplication 63377589Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsApplication 63367781Pending
- Pharmaceutical Compositions Comprising Wrn Helicase InhibitorsApplication 63367789Pending
- Compounds Selective For JAK1 And Methods Of UseApplication PCTUS2022030811Pending
- Compounds Selective For JAK1 And Methods Of UseApplication 63192908Pending
- Compounds And Methods For Modulating Immune-related ProteinsApplication PCTUS2020055690Pending
- Substituted Isoindolinones As Modulators Of Cereblon-mediated Neo-substrate RecruitmentApplication PCTUS2019064763Pending
- Compounds And Methods For Modulating Immune-related ProteinsApplication 62916172Pending
- Compounds And Methods Of Modulating Protein DegradationApplication PCTUS2018053146Pending
- Compounds And Methods Of Modulating Protein DegradationApplication 62564184Pending
- Method For Catalytically Synthesizing Single Chiral 2-ARYL-SUBSTITUTED Nitrogen-containing Heterocyclic Derivative By Means Of Imine Reductase, And Use ThereofApplication 19603472Pending
- RAS-PI3K Inhibitors For The Treatment Of Cancer And Immunological DiseasesApplication 19523521Pending
- KEAP1 Inhibitors And Uses ThereofApplication PCTUS2025059359Pending
- Compounds And Methods For Modulating RAS-PI3KApplication 19157021Pending
- KEAP1 Inhibitors And Uses ThereofApplication PCTUS2025059362Pending
- KEAP1 Inhibitors And Uses ThereofApplication 63733763Pending
- KEAP1 Inhibitors And Uses ThereofApplication 63733875Pending
Related companies, and why
- NEURONASAL INCSimilar federal contract value in Biotech · null in contracts
- EtiomeSimilar federal contract value in Biotech · null in contracts
- TEMPRIAN ONCOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- AlumisSimilar federal contract value in Biotech · null in contracts
- AUCTUS BIOLOGICS, INC.Similar federal contract value in Biotech · null in contracts
- VIOME LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .